Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

5 questions · 5 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 4 · 80%Moderate 1 · 20%High 0 · 0%

Single‐immune checkpoint inhibitors (ICIs) vs chemotherapy alone

Overall survival (OS) · People with advanced non‐small cell lung cancer

Single‐immune checkpoint inhibitors (ICIs) probably leads to lower overall survival (OS) compared with chemotherapy (moderate certainty).

1 finding from 1 review

Single‐immune checkpoint inhibitors (ICIs) vs chemotherapy alone

Progression‐free survival · People with advanced non‐small cell lung cancer

Single‐immune checkpoint inhibitors (ICIs) may leads to lower progression‐free survival (PFS) compared with chemotherapy (low certainty).

1 finding from 1 review

Single‐immune checkpoint inhibitors (ICIs) vs chemotherapy alone

Overall response rate (ORR), · People with advanced non‐small cell lung cancer

Single‐immune checkpoint inhibitors (ICIs) may leads to higher overall response rate (ORR) compared with chemotherapy (low certainty).

1 finding from 1 review

Single‐immune checkpoint inhibitors (ICIs) vs chemotherapy alone

Grades 3 and 4 adverse events · People with advanced non‐small cell lung cancer

Single‐immune checkpoint inhibitors (ICIs) may leads to lower adverse Events grade 3‐4 compared with chemotherapy (low certainty).

1 finding from 1 review

Single‐immune checkpoint inhibitors (ICIs) vs chemotherapy alone

QoL · People with advanced non‐small cell lung cancer

Single‐immune checkpoint inhibitors (ICIs) may leads to higher QOL‐C30 GHS/QOL (range 0‐100) ‐ change from baseline to week 15 compared with chemotherapy (low certainty).

1 finding from 1 review